INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG ..

2025 IASLC World Conference on Lung Cancer

 

September 6-9, 2025 Barcelona
Close
N. Poster
Poster title
Applicant name
Status
  1-P3 Deep Learning-Based CT Analysis Enhances Lung Cancer Risk Prediction in Never Smoking Women Alexis Chidi Received Received
  1-PT1-3 Enhancing Alectinib Efficacy in ALK positive Non-Small Cell Lung Cancer by Targeting mTOR Sofia Merajver Received Received
  1-P3 Unseen Risks: Rethinking Lung Cancer Screening for Hispanic Communities Coral Olazagasti Received Received
  1-P3 Lung Cancer in Incidentally Detected Pulmonary Nodules: Stratified Analysis by Smoking History and Nodule Morphology Filippe Moura de Gouva Received Received
  1-P3 Physical Characterization of PM2.5 - Effects on Cellular Uptake, Dispersion, and Lung Cell Interactions Isabella Mendoza Montealegre Received Received
  1-P3 Income, Tumour Stage, and Treatment in Patients With Non-Small Cell Lung Cancer: A Population-Based Study in the Netherlands Anouk Eijkelboom Received Received
  1-P3 IMPRINT-Lung: Single-Arm, Multi-Center Phase II Trial of Immunotherapy With Pembrolizumab for Interception of High-Risk Lung Nodules Jianjun Zhang Received Received
  1-P3 Lung Cancer Characteristics and Survival Among Smokers, Former Smokers, and Never Smokers Within an Australian Lung Cancer Registry rob stirling Received Received
  1-P3 Economic Burden of Radon Attributable Non-Small Cell Lung Cancer: A Cost Analysis David Griffin Received Received
  1-P3 Comparison of Age-Adjusted Charlson Comorbidity Index and Modified Frailty Index as a Postoperative Prognostic Indicator for Lung Cancer Masaya Yotsukura Received Received
  1-P3 Respiratory Hazard Index Is Associated With Lung Cancer Development in Underrepresented Lung Cancer Screening Individuals Frank Weinberg Received Received
  1-P3 10 Years Post Implementation of a Smoking Cessation (SC) Program in Regional Cancer Centres in Ontario, Canada:Successes and Ongoing Challenges William Evans Received Received
  1-P3 Socioeconomic Inequalities and Lung Cancer Outcomes: Evidence From an Integrated EHR Database and State Cancer Registry Data Tae Yoon Lee Received Received
  1-PT1 Large Language Models to Extract Smoking History From Clinical Notes in EHR to Evaluate Lung Cancer Surveillance Strategies Tae Yoon Lee Received Received
  1-P3 Asian-Americans With Tobacco Use History Are Less Often Eligible for Screening Than White Individuals With Lung Cancer Julie Barta Received Received
  1-P3 Survival Determinants and Socio-Demographic Disparities in Early Onset Lung Cancer in Young Adults: Insights From AI Modeling Maroun Bou Zerdan Received Received
  1-P3 Lung Cancer Risk Factors in 35,530 People From the UKLS Trial Who Have Never Smoked Lucy Shire Received Received
  2-P2 Identification of Deruxtecan-Induced Methylome Signature in NSCLC Cell Lines Arjan Gower Received Received
  2-P2 Synergistic Antitumor Effect of an XPO1 Inhibitor And/Or Sotorasib With V-ATPase Inhibitors Pretreatment in KRAS G12C NSCLC Jèssica González Received Received
  2-P2 Fulzerasib, a KRAS-G12C Inhibitor, Has Synergistic Antitumor Effect With Omeprazole Pretreatment in KRAS G12C NSCLC Mengxin Zhou Received Received
  2-PT1 GBC-11004: An AI-Driven Novel Kinase Target With Potential to Overcome Osimertinib Resistance in NSCLC Jihye Ryu Received Received
  2-P2 V-Atpase Inhibitors Enhance the Effect of Tepotinib (c-Met Inhibitor) or RMC-6236 (Pan-Ras(ON) Inhibitor) in KRAS-Mutant NSCLC Kevin Valencia-Clua Received Received
  2-P2 Canakinumab Interception Trial and Preclinical Studies Reveal Stage-Dependent Biology in Lung Cancer and Precancers Jianjun Zhang Received Received
  3-P3 Oxydock: Optimizing Lung Cancer-Targeted Therapy Through Oxygen-Responsive Molecular Docking Arnav Pemmaraju Received Received
  3-P3 Proteomic Analysis of Pleural Mesothelioma Tetsuzo Tagawa Received Received
  3-PT1 Precision Medicine Platform to Guide the Treatment of NSCLC Sofia Merajver Received Received
  3-P3 XPO1 Inhibition Reduces Tumor Growth Potential by Inhibiting Wnt Signaling Pathway in Lung Squamous Cell Carcinoma Vidushi Durani Received Received
  3-P3 Multi-Omic Characterization of ALK Fusion LUADs Reveals Overactivation of DNA Replication as a Contributor to ALK TKI Resistance Esther Redin Received Received
  3-P3 Tumor Treating Fields (TTFields) Downregulate DNA Repair and Show Efficacy in Small Cell Lung Carcinoma Preclinical Models Sinead Stewart Received Received
  3-P3 Tumor Treating Fields (TTFields) Concomitantly With Anti-PD-1 and Cisplatin in a Mouse Model of Non-Small Cell Lung Cancer Sinead Stewart Received Received
  3-P3 Immune-Related Gene Expression Profiling and ALK-TKI Efficacy for Patients With ALK-Rearranged Non-Small Cell Cancer Takashi Kurosaki Received Received
  3-PT1 An AI-Based Predictive Tool for Druggable Mutations in Lung Cancer Using Nationwide Comprehensive Genomic Profiling Data Hiroaki Ikushima Received Received
  3-P3 Rb Inactivation as a Hallmark of Squamous Transformation in EGFR-Mutant Lung Cancers Mark Jeng Received Received
  4-P1 The Coincidental Findings of Lung Nodules With AI-Assisted Chest X-Rays in the Tuberculosis Screening Project Prakaitip Susilparat Received Received
  4-PT1 Incidental Pulmonary Nodule Programs (IPN) Working Together With LDCT Scans and Artificial Intelligence (AI) Increase Lung Cancer Detection Luis Raez Received Received
  4-P1 New Nodule Lung Cancer in the UK Lung Cancer Screening Trial: Characteristics and Comparison With NELSON Michael Davies Received Received
  4-P1 AI Performance for Lung Nodule Growth in UK Lung Cancer Screening: Expert Consensus and Histological Validation Michael Davies Received Received
  4-P1 The Impact of Reconstruction Kernel and Hounsfield Unit Threshold on Emphysema Quantification From Lung Cancer Screening Data Hailan Liu Received Received
  4-P1 Performance of AI Vs. Radiologists in the 4-IN-THE-LUNG-RUN Lung Cancer Screening Trial: Annual Follow-Up Results Daiwei Han Received Received
  4-P1 Size Distribution and Short-Term Progression of New Nodules From the 4ITLR Lung Cancer Screening Trial Daiwei Han Received Received
  4-P1 Moving Forward in Early Detection: The ACS/NLCRT Best Practice Guide for Building Lung Cancer Early Detection Programs Carey Thomson Received Received
  4-P1 Lung Cancer Screening Completion Rates as Predicted by Social Deprivation Randi Williams Received Received
  4-PT1 Performance of Lung Nodule and Cancer Risk Calculators in Identifying Primary Lung Cancer Across Screening and Incidental Nodule Populations Francisco Aristofanes Coelho Sarmento Neto Received Received
  4-P1 Barriers to Lung Cancer Screening Among Overdue Patients; a Quality Improvement Initiative Sania Choudhary Received Received
  4-P1 Implementation of a Lung Cancer Risk Prediction Algorithm: Early Findings From the Lungflag™ Pilot at Geisinger Health System Matthew Facktor Received Received
  4-P1 Poor Utilization of Lung Cancer Screening Among Cancer Survivors in the United States Alexis Chidi Received Received
  4-PT1 Biomarker-Based Eligibility for Lung Cancer Screening - Validation of Protein-Based INTEGRAL-Risk Model in the LC3 Consortium Mattias Johansson Received Received
  4-P1 Effect of Social Determinants of Health on Lung Cancer Screening Uptake in the U.S Elizabeth Seitz Received Received
  4-P1 Evaluating the Impact of Electronic Reminders on Lung Cancer Screening Carolyn Chang Received Received
  4-P1 Impact of lung cancer screening eligibility criteria on participants´ characteristics and healthcare resources María Olivia Cabrera Godoy Received Received
  5-P2 Evolution and Survival Impact of Endobronchial Ultrasound (EBUS) Adequacy in a Population-Based Lung Cancer Cohort Olawale Akinbobola Received Received
  5-P2 European Single-Center Validation of the 9Th TNM Staging System in Over 3,300 Surgically Treated NSCLC Patients Inna Schott Received Received
  6-P2 ASPiRATION. Australian Nationwide Cohort Study to Assess Impact of Comprehensive Genomic Profiling in Metastatic Lung Cancer Michelle Cummins Received Received
  6-P2 Molecular Profiling of Lung Cancer Brain Metastases: Analysis Between Liquid Biopsy and Brain Metastasis Tissue Results Rupesh Kotecha, MD Received Received
  6-P2 Initial Biomarker Results From the Phase 2A Study of AFM24 With Atezolizumab in Patients With Advanced/Metastatic NSCLC Daniela Morales Espinosa Received Received
  6-P2 Clonal Hematopoiesis and Its Association With Lung Cancer Incidence and Immunotherapy Response: A Meta-Analysis Bansal Dhruv Received Received
  6-P2 Differential Gene Expression and Pathway Analysis of Invasive Mucinous Adenocarcinoma Seoin Kim Received Received
  6-P2 Actionable Mutation Profiles and Survival Outcomes in Invasive Mucinous Adenocarcinoma of the Lung Seoin Kim Received Received
  6-P2 DYNAMALK: DYNAMic ct-DNA in ALK+ NSCLC Under the Australasian Thoracic Cancers Longitudinal Cohort Biobank Study (AURORA) Malinda Itchins Received Received
  6-P2 Survival and Mutational Differences of GPER and Estrogen Receptor (ER) in NSCLC Robert Hsu Received Received
  6-P2 Using a Personalized, Tumor-Informed Circulating DNA (ctDNA) to Monitor Treatment Outcomes in Lung Cancer Patients Charuta Palsuledesai Received Received
  6-P2 A Novel Predictive Gene Signature for Liver Metastasis (LM) in NSCLC Using a Comprehensive Linked Clinical-Molecular Database Darren Johnson Received Received
  6-P2 TP53/RB1-Mutant Squamous Cell Lung Cancers: Clinicopathologic Features and Outcomes Mark Kris Received Received
  6-P2 Factors Impacting Receiving EGFR Test Results Before Initial Treatment Among Stage IV Non-Small Cell Lung Cancer Patients Mike Gart Received Received
  6-P2 Distinct Clinical and Biological Features of Five SCLC Subtypes Identified by Plasma Proteomic Analysis Yehonatan Elon Received Received
  6-P2 Metabolite Enrichment Patterns Correlate With Race, Gender and BMI in Lung Cancer Patients Joshua Pothen Received Received
  6-P2 Assessment of Molecular Testing in Stage IV Non-Small Cell Lung Cancer Patients Across American Oncology Network Mike Gart Received Received
  6-P2 GPC3 Upregulation After Neoadjuvant Chemoimmunotherapy Associates With Adverse Outcomes and Tumor Heterogeneity in Squamous NSCLC linqiang Jiang Received Received
  6-P2 Title: Prognostic Impact of TP53 Co-Mutations with EGFR vs KRAS in Advanced Non-Small Cell Lung Cancer: A cBioPortal Analysis Divya Chukkalore Received Received
  6-P2 Adoption of a 50-Gene Targeted Next Generation Sequencing Hotspot Panel in Non-Small Cell Lung Cancer in a Tertiary Institution in Singapore Kenneth Sooi Received Received
  6-P2 Circulating Tumour Cells, Spread Through Air Space and Lymph-Nodal Micrometastasis in Surgically Resected Early-Stage NSCLC Pietro Bertoglio Received Received
  6-P2 More Than a Mutation: Prevalence of HER2 Overexpression, Amplification, and Mutations by Histology in NSCLC Jennifer Marks Received Received
  7-P1 Lobectomy Versus Multi-Segmentectomy for Left Upper Lobe Lung Cancer: A Propensity Score-Matched Analysis Naoki Takeno Received Received
  7-P1 Adjuvant Immunotherapy for Clinically Node-Negative Non-Small Cell Lung Cancer Giorgio Caturegli Received Received
  7-P1 AI-Based 3D Reconstruction in Lung Surgery Sayzana Kassahun Received Received
  7-P1 Effect of Surgical Resection on Quality of Life in Older Adults for Stage IA Non-Small Cell Lung Cancer Jiafang Zhang Received Received
  7-P1 Using Tissue and Blood to Find Oncogenic Drivers Upfront in Patients With Lung Cancer Evaluated for Neoadjuvant Therapy-LEADER Jules Lin Received Received
  7-P1 Peri-Operative Immune Cell Profiling in Lung Cancer Resection: A Longitudinal Study Laura Staunton Received Received
  7-P1 Detection of ctDNA Prior to Neoadjuvant Osimertinib Treatment Correlates With Decreased EFS in EGFR-Mutated NSCLC Tyiesha Brown Received Received
  7-P1 Toxicity Profile for Connective Tissue Disease Patients Treated With Lung Stereotactic Body Radiation Therapy Gregory Videtic Received Received
  7-PT1 Neoadjuvant Ensartinib for ALK-Positive (ALK) Non-Small Cell Lung Cancer (NSCLC): A Multicenter, Real-World Study Miao Jin Received Received
  7-P1 Real-World Biomarker Testing and Treatment Initiation in Patients With Resected Early-Stage NSCLC (eNSCLC) in the US and UK Darren Johnson Received Received
  8-P2 Neoadjuvant Chemoimmunotherapy in Resectable NSCLC. Real-World Evidence From a Spanish Multicenter Cohort Isabel Castellano Carneiro Received Received
  8-P2 Radiation Dose to the Heart and Cardiac Substructures Associated With Adverse Cardiac Events in Locally-Advanced Non-Small Cell Lung Cancer Emily Harris Received Received
  8-P2 Ia-Based Prediction in NSCLC Patients Undergoing Neoadjuvant Radiochemotherapy Claudia Tacconi Received Received
  8-P2 Survival Outcomes in Locally Advanced NSCLC Patients Converted to Resectable Disease by Neoadjuvant Therapy Ozden Altundag Received Received
  8-P2 Sequencing of Chemoimmunotherapy in Resectable Locally Advanced NSCLC: Single Center Experience Pranay Adavelly Received Received
  8-P2 Impact of Neoadjuvant Chemoimmunotherapy vs Chemotherapy in Stage III NSCLC: Real-World Analysis from Spanish ReSECT Registry Xavier Vaíllo Received Received
  8-P2 Treatment Options and Prognosis for Lung Cancer in Elderly Patients(?80 Years Old) Mari Shinoda Received Received
  8-P2 Pacific Real-World Experience at Hospital Doce De Octubre Temes Mariana Received Received
  8-P2 Double Lung Transplantation in Patients With Recent History of Malignancy Young Kwang Chae Received Received
  8-P2 VMAT vs IMRT Technique in Locally Advanced Lung Cancer Radiotherapy Treatment -Pulmonary Toxicity and Dosimetric Evaluation Slavica Maric Received Received
  8-P2 Outcomes From a Phase II Study of Hypofractionated Chemoradiation and Consolidation Immunotherapy in Locally-Advanced NSCLC Gregory Vlacich Received Received
  8-P2 Proton Beam Therapy for Lung Cancer in Patients With Interstitial Lung Disease: Initial Experience From the United Kingdom Caroline Maguire Received Received
  8-P2 Lymph Node Yield and Survival Among Lung Cancer Patients Treated With Neoadjuvant Systemic Therapy Giorgio Caturegli Received Received
  8-P2 Safety and Biomarker Analysis of Nrg-Lu004: Phase I Trial of Radiotherapy With Durvalumab in PD-L1 High LA-NSCLC Steven Lin Received Received
  8-PT1 Chemoradiation/Immunotherapy(IO) for Stageiii NSCLC: Timing of IO, and the Benefits/Selection in Elderly & Black Patients John Varlotto Received Received
  9-P3 Stereotactic Mr-Guided Adaptive Radiotherapy (SMART) for Ultracentral Non-Small Cell Lung Cancer (NSCLC) Elena Moreno-Olmedo Received Received
  9-PT1 Double Lung Transplantation in Patients With Metastatic Lung-Limited Non-Small Cell Lung Carcinoma (NSCLC): A Case Series Young Kwang Chae Received Received
  9-P3 Tumor Treating Fields for Patients With Metastatic Non-Small Cell Lung Cancer: Real World First Experience Rupesh Kotecha, MD Received Received
  9-P3 Validation of Lung Specific-Graded Prognostic Assessment Score in NSCLC With Brain Metastases From India Sarath M S Received Received
  10-P2 Maintenance Pemetrexed/Pembrolizumab vs Maintenance Pembrolizumab Alone in Advanced Non-Squamous Non-Small Cell Lung Cancer Garth Strohbehn Received Received
  10-P2 Long-Term Pemetrexed Administration Poses Risk of Renal Function Decline Tomoki Tamura Received Received
  10-P2 Sunvozertinib Combined With Bevacizumab in Previously Treated Advanced NSCLC With EGFR Exon 20 Insertion Mutations Yiman Wang Received Received
  10-P2 Dual PARG-TOP1 Inhibition Exacerbates DNA-Protein Crosslinks and Replication Stress: A Promising Strategy for Enhancing Top1i-ADC Efficacy Reeja Maskey Received Received
  10-P2 Combined Immunoscore for Predictive Stratification of Unresectable Non-Small Cell Lung Cancer Oussama Aazzane Received Received
  10-PT2 Peripheral Neuropathy and Efficacy of Telisotuzumab Vedotin in c-Met Protein-Overexpressing NSCLC: LUMINOSITY Study Elaine Jennings Received Received
  10-P2 Docetaxel in NSCLC: A Multi-Centre Real World Evidence Analysis in the Immunotherapy Era Christopher Theriau Received Received
  11-P1 Tiragolumab Plus Atezolizumab and Bevacizumab in Immunotherapy-Refractory, Pd-L1+, Advanced Non-Squamous Non-Small Cell Lung Cancer Joshua Reuss Received Received
  11-P1 Measuring the Effect of Age and Ethnicity on Outcomes in Patients With Advanced Lung Cancer Treated With Immunotherapy: A New Zealand Analysis Robert Cole Received Received
  11-P1 Phase Ib Study of Golidocitinib Plus Anti-PD-1 in Anti-PD-1 Treated Advanced NSCLC: Dose-Escalation Safety Using BOIN Design Yingqi Lin Received Received
  11-P1 Survival Impact of Pneumonitis in Older Patients With Non-Squamous NSCLC Treated With Pembrolizumab and Pemetrexed: Insights From CJLSG1901 YOSHIHITO KOGURE Received Received
  11-P1 Optimal Immunotherapy Regimen for STK11 or KEAP1 Mutant Metastatic Non-Small Cell Lung Cancer Natalie Shammas Received Received
  11-P1 Tumor-Derived Complement Factor B Drives Tumor Growth and Anti-PD-1 Resistance in STK11-Mutant Lung Adenocarcinoma Edwin Yau Received Received
  11-P1 Deep Learning Histopathology Model for PD-L1 (TPS) and Immunotherapy Outcome Prediction in Non-Small Cell Lung Cancer Masoud Tafavvoghi Received Received
  11-P1 Immune Cell Infiltration and Spatial Associations in the Tumor Microenvironment Following Dual ICI or ICI-Chemotherapy Natalie Vokes Received Received
  11-P1 Identifying Patients Cured From Metastatic Non-Small Cell Lung Cancer (mNSCLC) With Anti-PD-(L)1 Therapy Natalie Vokes Received Received
  11-PT2 Rescue by Radiotherapy and Anti-CTLA4/PD-1 After Failure of Anti-PD-1 Therapy in Metastatic NSCLC Patients: the RECLAIM study Ezgi Ulas Received Received
  11-P1 Gut Microbiota: Associations Between Composition and Response to Immunotherapy in Non-Small Cell Lung Cancer Gisele Moreira Received Received
  11-P1 Genomic Characterticers, Survival and Prognostic Analysis of Advanced NSCLC With Kirsten Rat Sarcoma Mutations With Brain Metastases Yi Chen Received Received
  11-P1 Association Between CD274 (PD-L1) Gene Expression and PD-L1 Immunohistochemistry in Non-Small Cell Lung Cancer Specimens Rachel Evans Received Received
  11-P1 Interstitial Lung Abnormalities and MUC5B Polymorphism in Immune Checkpoint Inhibitor Pneumonitis Mehmet Altan Received Received
  11-P1 Survival Outcomes in Advanced Pulmonary Sarcomatoid Carcinoma Treated With Immunotherapy: An NCDB Analysis Ujjwal Karki Received Received
  11-P1 Real-World Prognosis of Non-Squamous NSCLC Patients With Liver, Bone, or Brain Metastases Treated With Frontline Therapies Elaine Jennings Received Received
  11-P1 Strengthening Real World Evidence Generation Through an Expanding Multicenter Canadian Lung Cancer Registry Paul Wheatley-Price Received Received
  11-P1 Long-Term Efficacy of Immune Checkpoint Inhibitors in Pulmonary Cancer With Rhabdoid Features: A Single-Center Retrospective Analysis May-Lucie Meyer Received Received
  11-P1 Impact of Radiotherapy and Immune Checkpoint Inhibitor Combination in Advanced NSCLC: Real-World Data (RWD) Analysis Joaquim Bosch-Barrera Received Received
  11-P1 Preliminary Safety and efficacy of restorative Microbiota Therapy with Chemoimmunotherapy in Metastatic Non-Samll Cell Lung Cancer (RMT in NSCLC) Amit Kulkarni Received Received
  12-P3 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients Giuseppe Bronte Received Received
  12-P3 Concurrent KRAS Mutations Render Single-Agent EGFR Inhibitors Futile in Advanced NSCLC Misako Nagasaka Received Received
  12-P3 Rezivertinib in EGFR-Mutated NSCLC Patients With Cns Metastases: Cns Efficacy From Phase 3 RAZOR Study Jirong Peng Received Received
  12-P3 Rezivertinib in Advanced NSCLC Patients With EGFR T790M Mutation via Tissue/Plasma Samples: Pooled Analysis of 2 Clinical Studies Yanqiu Zhao Received Received
  12-P3 Medication Adherence to Osimertinib in Patients Diagnosed With Metastatic Non Small Cell Lung Cancer Katerine Dumais Received Received
  12-P3 The Primary Endpoint Analysis of RELAY-Effusion; a Phase II Study of Ramucirumab Plus Erlotinib in EGFR-Mutated NSCLC With Pleural Effusion Naoko Katsurada Received Received
  12-P3 Long-Term Real-World Outcomes of Sotorasib in Second-Line and Beyond Treatment of KRAS G12C-Mutated Advanced NSCLC Tim Harrison Received Received
  12-PT2 Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Brain Metastases at Baseline: Beamion LUNG-1 Tessa Cleaver Received Received
  12-P3 Adapting RECIST for Real-World Data: Independent Imaging Read Methodology Over Successive Treatments in a NSCLC Data Registry Syneos Health Received Received
  12-P3 Safety and Patient-Reported Outcomes With Tepotinib in Patients With METex14 Skipping NSCLC: =3-Years Follow-Up of VISION Syneos Health Received Received
  12-P3 Clinical Effectiveness and Safety of Tepotinib in Patients From Germany With MET Exon14 Skipping NSCLC: A Case Series Syneos Health Received Received
  12-P3 Reduced Survival in Black Patients With EGFR-Mutant NSCLC Barliz Waissengrin Received Received
  12-P3 First-Line Lazertinib With or Without Local Ablative Radiotherapy in Oligo-Metastatic EGFR-Mutant NSCLC Jii Bum Dr. Received Received
  12-P3 Phase II Trial of First-Line Double-Dose Firmonertinib in Locally Advanced or Metastatic NSCLC With EGFR L858R (FIRM Study) meiqi shi Received Received
  12-PT2 Osimertinib Combined With Tegavivint Is Safe and Tolerable as First-Line Therapy in Patients With Metastatic EGFR-Mutated NSCLC Regan Memmott Received Received
  12-P3 Pralsetinib (Phase 1/2 ARROW Trial) Compared With Best Available Therapy (External Control) in Pretreated RET Fusion+ NSCLC Angela Lax Received Received
  12-P3 Taletrectinib, a Next Generation Selective ROS1 Inhibitor, Exhibits a Differentiated Profile in ROS1 Fusion Models Sean ODonnell Received Received
  12-P3 Retrospective Analysis of Age, EGFR Mutation Type, and TP53 Co-Mutation on Survival Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Eric Singhi Received Received
  12-P3 Predicting Osimertinib-Induced Pneumonitis in EGFR-Mutated NSCLC Using Multi-Modal Machine Learning Model Kyujiro Nibuya Received Received
  12-P3 Multicenter Retrospective Study of Selpercatinib Treatment for Advanced or Recurrent RET Fusion-Positive NSCLC in Japan YASUHIRO MIHASHI Received Received
  12-P3 A Phase II Study of Sunvozertinib Combined With Anlotinib in Treatment-Naïve NSCLC With EGFR Sensitive Mutations and Co-Mutations (WU-KONG32) Yingqi Lin Received Received
  12-P3 A Phase II Study of Sunvozertinib Combined With Anlotinib in NSCLC Patients Harboring EGFR Ex20Ins and Uncommon EGFR Mutations Yingqi Lin Received Received
  12-P3 A Phase II Study of Sunvozertinib Combined With Chemotherapy in EGFR-TKIs Resistant EGFRm Advanced NSCLC Patients(WU-KONG36) Yingqi Lin Received Received
  12-P3 Tepotinib Efficacy in Poor Performance Status and Elderly Patients With MET Exon 14 Skipping NSCLC: A RELA-MET Subanalysis Kazuhiro Nishiyama Received Received
  12-P3 Updated Clinical Results From FURTHER: A Study of Firmonertinib in TKI-Naive, Advanced NSCLC With EGFR PACC Mutations William Leung Received Received
  12-P3 Real-World Treatment of Osimertinib Monotherapy Versus Combination Therapy in Stage IV Non-Small Cell Lung Cancer Patients Mike Gart Received Received
  13-P3 Real-World Implementation of Immunotherapy for Stage III-IV Small Cell Lung Cancer: Insights From the National Cancer Database (2016-2021) Brittany Morguelan Received Received
  13-P3 Real-World Outcomes of Prophylactic Cranial Irradiation (PCI) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the US Darren Johnson Received Received
  13-PT2 Real-World Multi-Institution Analysis of Patients With Small Cell Lung Cancer Treated With Tarlatamab Alissa Cooper Received Received
  13-P3 Survival Outcomes in Advanced Large Cell Neuroendocrine Carcinoma of the Lung in Immunotherapy Era: An NCDB Analysis Ujjwal Karki Received Received
  13-P3 Real-World Effectiveness and Safety of Lurbinectedin for Small Cell Lung Cancer (SCLC): Updates From Jazz EMERGE 402 Jenny Pena Received Received
  13-P3 A Phase II Study of Vobramitamab Duocarmazine in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer Tina Roy Received Received
  13-P3 First-In-Human Study of 225Ac-ABD147 for SCLC and LCNEC Post-Chemotherapy: Pharmacokinetics, Biodistribution and Safety Insights Sean Carlin Received Received
  14-P3 Real-World Outcomes and Toxicity of First-Line Dual Immunotherapy in Unresectable Pleural Mesothelioma Beatriz Jimenez Munarriz Beatriz Received Received
  14-PT2 SYSTEMS-2: A Randomised Phase II Study of Radiotherapy Dose Escalation in Pleural Mesothelioma iain phillips Received Received
  14-P3 MTAP Deficiency in Thymic Epithelial Tumors Jennifer Marks Received Received
  14-P3 Outcomes to Systemic Standard-Of-Care Therapies in Patients With MTAP-Deleted Advanced Non-Small Cell Lung Cancer Julian Huang Received Received
  15-P2 Quality of Life for Lung Cancer Survivors Asha Kodan Received Received
  15-P2 A Shared Decision Aid for First-Line Treatments of ALK Advanced Non-Small Cell Lung Cancer: A Patient-Centered Approach Caitlyn Matuska Received Received
  15-P2 Impact of an Incidental Pulmonary Nodule Course Series on the Professional Development of Under-Resourced Multidisciplinary Teams Holly Sanders Received Received
  15-P2 Early Lung Cancer Detection and Multidisciplinary Care Simon Tye Received Received
  15-PT2 ?Examining the Role of Frailty Assessments in Older Adult With Lung Cancer to Identify Patient Vulnerabilities and Exploring Patient Outcomes Philip Papayanis Received Received
  15-P2 Influence of Preoperative Mental Health on the Postoperative Outcome and Quality of Life After Anatomic Lung Resection Uyen-Thao Le Received Received
  15-P2 Symptom Screening Using the Patient-Generated Subjective Global Assessment Adds Value to Routine Clinical Review Chris Smith Received Received
  15-P2 Predictive Value of LIPI Score in the Response to Immunotherapy in Very Elderly Patients With Advanced Non-Small Cell Cancer Alejandro Olivares Hernández Received Received
  15-PT2 Impact of Physical Exercise on Quality of Life in Patients With Advanced Lung Cancer Ana López-Martín Received Received
  15-P2 Preliminary Results on Feasibility of Virtual Delivery of Exercise Therapy for Mitigation of Lung Cancer Decline Lauren Curry Received Received
  15-P2 A Shared Decision Aid for First-Line Treatments of ALK+ Advanced Non-Small Cell Lung Cancer: A Patient-Centered Approach Thomas Stinchcombe Received Received
  16-P3 Co-Designing a Resource to Reduce Stigma in Lung Cancer Screening Kathleen McFadden Received Received
  16-PT2 Patients Who Reach Clinical Trials and Those Who Do Not,A Structural Analysis of Access Disparities in Japan Kazuo Hasegawa Received Received
  16-P3 Frontline Insights in US Payer Barriers Impacting Patient Access and Participation in Comprehensive Lung Cancer Screening Programs Angela Barry Received Received
  16-P3 The Saving Lungs Behind the Chair Model Is Increasing Lung Cancer Awareness in US Black Communities Donna Whitney Received Received
  16-PT2 Survivorship Needs for Patients With NSCLC Treated With Oral Targeted Therapies Matthew Guo Received Received
  16-P3 Improving Lung Cancer Screening Uptake in 20 Disadvantaged New York Counties: Early Findings From a Demonstration Project Joelle Fathi Received Received
  16-P3 Giving Back - Co-Creation of Data Dashboard to Share Survey Results With Patients and Caregivers Bellinda King-Kallimanis Received Received
  16-P3 The Role of Neighborhood Deprivation in Lung Cancer Diagnosis and Treatment Brittney Nichols Received Received
  16-P3 Facilitators to Patient Advocacy Group-Led Engagement of Diverse, Community, Clinical Sites in Multiple Research Types Andrew Ciupek Received Received
  16-P3 The Development of a Patient Education Lung Cancer Nodal Staging Video Toolkit: American Cancer Society National Lung Cancer Roundtable Jeffrey Velotta Received Received
  16-P3 Lung Cancer Patients Understanding of and Involvement in Their Treatment and Care: Insights From a Global Patient Experience Survey Jackie Tebbs Received Received
  17-P1 Clinical and Molecular Characterization of Lung Cancer in Never-Smokers Identified Through an Incidental Nodule Program Jose Fernando Prado Moura Received Received
  17-P1 Real-World (RW) Study of Biomarker Testing Patterns Among Patients With Early-Stage Resected NSCLC in the United States Rajrupa Ghosh Received Received
  17-P1 Facilities and Workforce Available for Thoracic Oncologic Care and Research in Nigeria, a Low-Middle Income Country (LMIC) Simon Tye Received Received
  17-P1 Implementation of Lung Cancer Screening by Family Physicians in the U.S.: Results of a National Survey Robert Volk Received Received
  17-P1 Stage Iv Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Biomarker Testing Disparities and Outcomes: A Population-Based Study Surbhi Singhal Received Received
  17-P1 The Best Care One-Lung Program; a Pathway for Lung Cancer Screening in Primary Care Jessie MacDonald Received Received
  17-P1 Multidisciplinary Digital Platform for Independent Adjudication of ILD/Pneumonitis Related to T-DXd Treatment Marcos Aurelio Fonseca Magalhaes Filho Received Received
  17-P1 Role of Lung Microbiome on Precise Diagnosis of Patients With Checkpoint Inhibitor Pneumonia: Result From a Prospective Cohort Study Zhenhua Zhou Received Received
  17-P1 Lung Cancer Consensus: Uniting for a Healthier World Mary E. Bussell Received Received
  17-P1 Gender Disparities in Remote Patient Monitoring: Analysis From 973 Lung Cancer Patients Treated Across 42 Sites in France and Belgium Claudia Parisi Received Received
  17-P1 Real-World Insights on Treatment Patterns and Outcomes in ROS1 NSCLC: An Australian Multicenter Study (AURORA) Marliese Alexander Received Received
  17-P1 A Real-World Study of Advanced ALK-Fusion NSCLC Patients Receiving First-Line ALK-TKI Therapy with Telehealth Care Di Zheng Received Received
  17-P1 Assessing Sarcopenia in Lung Cancer: Feasibility and Training Considerations of Using Quantitative Imaging Metrics From CT Scans Chandana Adhikarla Received Received
  17-P1 Real-World Uptake of Immunotherapy for Stage III-IV Non-Small Cell Lung Cancer: Insights From the National Cancer Database (2016-2021) Brittany Morguelan Received Received
  17-P1 Real-World Outcomes With IO and Chemo-IO Demonstrate Unmet Need for 1L KRAS G12C-Mutant Advanced NSCLC in the US Kristin Sheffield Received Received
  17-PT2 Association of accelerated biological ageing with early-onset lung cancer and its prognosis: insights from a multicenter casecontrol study and the UK Biobank Yuxuan Liao Received Received
  17-P1 Perspectives on Health-Related Quality of Life Among Physicians and Patients With ALK-Positive NSCLC in China Qiang Wang Received Received
  17-P1 Correlation Between Clinical and Pathological Stage in Resected NSCLC Giordano Cittolin Santos Received Received
  17-P1 Victorian Lung Cancer Registry Impacts on Multi-Disciplinary Lung Cancer Meeting Presentation rob stirling Received Received
  17-PT2 Impact of Timely Treatment Initiation on Outcomes in Non-Small Cell Lung Cancer. a Registry Based Observational Study rob stirling Received Received
  17-P1 Impact of Concurrent Tissue and Liquid Comprehensive Genomic Profiling (CGP) on Receipt of First-Line (1L) Therapy in a NSCLC Jessica Lee Received Received
  17-P1 Developing a Multifaceted Implementation Strategy to Increase Clinical Trial Accruals in Thoracic Oncology Kadi Dick Received Received
  17-P1 Racial and Ethnic Disparities in Receipt of Guideline Concordant Treatment for Early-Stage NSCLC in Los Angeles County Albert Farias Received Received
  17-P1 Biomarker Testing Timeliness for Patients With Lung Cancer Bingtao Xiang Received Received
  17-P1 Treatment Changes Over 12 Months of Observation for ALK and EGFR-Positive NSCLC - Results From an Real-World Study Upal Basu Roy Received Received
  17-P1 Clinicomolecular Characteristics and Treatment Patterns in Stage IV NSCLC: A Retrospective Study From Southwestern Ontario M. Sara Kuruvilla Received Received
  17-P1 Concordance of HER2 Protein Overexpression by IHC and ERBB2 Gene Amplification by NGS in Lung Cancer Samrat yeramaneni Received Received
  17-P1 A Large-Scale Network Study on Impact of Immune Checkpoint Therapy in Metastatic Non-Small Cell Lung Cancer: The iCan mNSCLC Study-A-Thon Ilkka Ilonen Received Received
  18-P3 Quick Start Durvalumab: A Phase II Pilot Study of Early Durvalumab Initiation Following Chemoradiation in Unresectable Stage II-III NSCLC Stephanie Brinton Received Received
  18-P3 Phase 1b Study of a Novel Fluorescent Imaging Agent, LS301, for Lung Cancer Surgery to Localize Tumors and Assess Margins Nick Staten Received Received
  18-P3 A Phase II Study of Repotrectinib in ROS1-Positive Non-Small Cell Lung Cancer Patients With Active Brain Metastasis - REPOSE Olga Boix Received Received
  18-P3 TRIPL: Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer Angelica DAiello Received Received
  18-P3 First-In-Human Trial of PFL-241/STX-241 in Patients With Locally Advanced or Metastatic NSCLC Resistant to EGFR Tyrosine Kinase Inhibitors Mounia Yadini Foucart Received Received
  18-P3 Trial in Progress - RAsolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) Vs. Docetaxel in in Patients With Previously Treated RAS Mutant NSCLC sinem taylor Received Received
  18-P3 Efficacy and Safety of Ivonescimab Plus Chemotherapy for Recurrent/Metastatic Thymic Carcinoma: A Phase II Study (iThyme) Xue Hou Received Received
  18-P3 Adding Certolizumab to Neoadjuvant Chemoimmunotherapy - Control of Immune-Related Adverse Events and Prevention of Surgical Delays Paul Paik Received Received
  18-P3 BNT324-01: A Phase 1b/2 Trial of BNT324/DB-1311 (B7H3 ADC) With BNT327 (PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC) AURORA OBRATE Received Received
  18-P3 Alectinib as Adjuvant Therapy in Resected ALK-Positive NSCLC: A Prospective Multicenter Cohort Study in China &40527;&39134; &32918; Received Received
  18-P3 Trastuzumab Deruxtecan + Pembrolizumab as First-Line Treatment in HER2-Overexpressing, PD-L1 Tps <50% NSCLC (DESTINY-Lung06) Delphine Tinker Received Received
  18-P3 Phase II Study of CBDCA + Nab-PTX + Tremelimumab+Durvalumab for TTF-1 Negative Advanced non-sq NSCLC (WJOG17223L, TURNING) Motoko Tachihara Received Received
  18-P3 Immunotherapy Combined With Radiotherapy as Neoadjuvant Therapy in Resectable NSCLC: A Single Arm, Phase II Clinical Study Buhai Wang Received Received
  18-P3 A Randomized Comparative Effectiveness Trial of Perioperative Physical Activity in Older Adults With Lung Cancer and Their Family Caregivers Dan Raz Received Received
  18-P3 PRESERVE-003: A Phase 3 Study of Gotistobart Versus Docetaxel in Metastatic NSCLC After Progression on PD-(L)1 Inhibitors Susanne Eiglmeier Received Received
  18-P3 TACTI-004, a Phase 3 Trial of Eftilagimod Alfa Plus Pembrolizumab (P) Chemotherapy (C) vs Placebo P C in 1St Line NSCLC soumia cherif Received Received
  18-P3 Implementation Study of Lung Cancer Screening Combined With a Smoking Cessation RCT in the Flemish Region: The ZORALCS- and TAMIRO-Stop-Study Annemiek Snoeckx Received Received
  18-P3 Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer (NeoRADjuvant) Samuel Rosner Received Received
  18-P3 ARTEMIDE-Lung02: A Phase 3 Global Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for 1L Metastatic Squamous NSCLC Sam Bunting Received Received
  18-P3 First-In-Human Phase I/II Trial of PFL-002/VERT-002 in Locally Advanced or Metastatic Solid Tumors Including NSCLC With MET Alterations Mounia Yadini Foucart Received Received
  18-P3 Efficacy and Safety of Befotertinib Plus Icotinib in Advanced NSCLC With Uncommon EGFR Mutations: A Phase II Study (Icombine) Xue Hou Received Received
  18-P3 Combination of Osimertinib and Carotuximab for Advanced, EFGR-Mutated Non-Small Cell Lung Cancer Patients Karen Reckamp Received Received
  18-P3 Efficacy and Safety of Tislelizumab Combined With Tofacitinib and Docetaxel for NSCLC After Failure of First-Line Immunotherapy Wang Xie Received Received
  18-P3 SUNRAY-02: A Phase 3 Study of Olomorasib and Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC After Definitive Therapy Ernest Nadal Received Received
  18-P3 Predictive Role of Respiratory Function Tests on Lung Toxicity in Stage III NSCLC Under Chemo-Radiotherapy and Durvalumab: Preludio Trial Paola Maria Medusa Received Received
  34-P3-13 Tarlatamab Efficacy and Safety in Chinese Patients with Advanced Small Cell Lung Cancer: Phase 2 DeLLphi-307 Michelle Kang Received Received
  35-P3-13 Final Analysis of Phase Ib/II Trial of Niraparib/Temozolomide with Atezolizumab vs. Atezolizumab as Maintenance for ES-SCLC James Chauv Received Received
  54-P1-4 Breath-based Lung Cancer Detection: Initial Phase 2 Results for D5-Ethyl-β-D-glucuronide (OWL-EVO1) as a Lung Cancer Probe Aleksandra Higson Received Received
  71-P3-12 Efficacy and Safety of Pralsetinib in Patients With Advanced Ret Fusion-Positive NSCLC: Phase 1/2 ARROW Study Final Data Elena Dang Received Received
  75-P3-12 Final Analysis of Phase Ib/II Study of Osimertinib, Necitumumab and Trastuzumab for Refractory EGFR-Mutated Lung Cancer James Chauv Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
04:00
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

2025 IASLC World Conference on Lung Cancer

 

September 6-9, 2025 Barcelona
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 06/09/2025 TO 06/09/2025
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
Logo Cert